162 related articles for article (PubMed ID: 26259523)
1. A multimodal disease modifying approach to treat neuropathic pain--inhibition of soluble epoxide hydrolase (sEH).
Pillarisetti S; Khanna I
Drug Discov Today; 2015 Nov; 20(11):1382-90. PubMed ID: 26259523
[TBL] [Abstract][Full Text] [Related]
2. Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Wagner K; Yang J; Inceoglu B; Hammock BD
J Pain; 2014 Sep; 15(9):907-14. PubMed ID: 24924124
[TBL] [Abstract][Full Text] [Related]
3. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.
Pillarisetti S; Khanna I
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237
[TBL] [Abstract][Full Text] [Related]
4. Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.
Goswami SK; Inceoglu B; Yang J; Wan D; Kodani SD; da Silva CA; Morisseau C; Hammock BD
Toxicol Appl Pharmacol; 2015 Dec; 289(3):419-27. PubMed ID: 26522832
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
6. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways.
Inceoglu B; Jinks SL; Ulu A; Hegedus CM; Georgi K; Schmelzer KR; Wagner K; Jones PD; Morisseau C; Hammock BD
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18901-6. PubMed ID: 19028872
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.
Liao J; Hwang SH; Li H; Liu JY; Hammock BD; Yang GY
Anticancer Res; 2016 Jan; 36(1):27-37. PubMed ID: 26722025
[TBL] [Abstract][Full Text] [Related]
8. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.
Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M
Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314
[TBL] [Abstract][Full Text] [Related]
9. Computational insights into the known inhibitors of human soluble epoxide hydrolase.
Bzówka M; Mitusińska K; Hopko K; Góra A
Drug Discov Today; 2021 Aug; 26(8):1914-1921. PubMed ID: 34082135
[TBL] [Abstract][Full Text] [Related]
10. Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
Pallàs M; Vázquez S; Sanfeliu C; Galdeano C; Griñán-Ferré C
Biomolecules; 2020 May; 10(5):. PubMed ID: 32369955
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
12. Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor.
Sanders WG; Morisseau C; Hammock BD; Cheung AK; Terry CM
Am J Physiol Cell Physiol; 2012 Aug; 303(3):C278-90. PubMed ID: 22621785
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain.
Lee KSS; Ng JC; Yang J; Hwang SH; Morisseau C; Wagner K; Hammock BD
Bioorg Med Chem; 2020 Nov; 28(22):115735. PubMed ID: 33007552
[TBL] [Abstract][Full Text] [Related]
14. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
Lee KS; Liu JY; Wagner KM; Pakhomova S; Dong H; Morisseau C; Fu SH; Yang J; Wang P; Ulu A; Mate CA; Nguyen LV; Hwang SH; Edin ML; Mara AA; Wulff H; Newcomer ME; Zeldin DC; Hammock BD
J Med Chem; 2014 Aug; 57(16):7016-30. PubMed ID: 25079952
[TBL] [Abstract][Full Text] [Related]
15. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models.
Wagner K; Inceoglu B; Dong H; Yang J; Hwang SH; Jones P; Morisseau C; Hammock BD
Eur J Pharmacol; 2013 Jan; 700(1-3):93-101. PubMed ID: 23276668
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.
Inceoglu B; Jinks SL; Schmelzer KR; Waite T; Kim IH; Hammock BD
Life Sci; 2006 Nov; 79(24):2311-9. PubMed ID: 16962614
[TBL] [Abstract][Full Text] [Related]
18. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
19. Targeting epoxides for organ damage in hypertension.
Imig JD
J Cardiovasc Pharmacol; 2010 Oct; 56(4):329-35. PubMed ID: 20531214
[TBL] [Abstract][Full Text] [Related]
20. Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.
Das Mahapatra A; Choubey R; Datta B
Molecules; 2020 Nov; 25(23):. PubMed ID: 33255197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
